Company: PFSA
Filing Date: 2025-02-12
Form Type: S-4/A
Source: 0001213900-25-012354
Chunk: 200

Company: Profusa, Inc.
Filing Date: 2025-02-12
Form: S-4/A
Chunk 200
---
 in the U.S. or foreign jurisdictions relating to New Profusa’s business, or speculation regarding such changes; •conditions or trends in the diagnostic, medical device or biotechnology industries; 89 •stock market price and volume fluctuations of comparable companies; •announcements by New Profusa or its competitors of significant acquisitions, strategic partnerships or divestitures; •significant lawsuits or announcements of investigations or regulatory scrutiny of its operations or lawsuits filed against New Profusa; •recruitment or departure of key personnel; •investors’ general perception of New Profusa’s business or management; •trading volume of New Profusa Common Stock; •overall performance of the equity markets; •publication of research reports about New Profusa or its industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; •the impacts of the ongoing COVID -19pandemic and related restrictions; •general political and economic conditions; and •other events or factors, many of which are beyond Profusa’s control. In addition, in the past, stockholders have initiated class action lawsuits against public companies following periods of volatility in the market prices of these companies’ stock. Such litigation, if instituted against New Profusa, could cause it to incur substantial costs and divert management’s attention and resources from its business. Upon the completion of the Business Combination, the Profusa shareholders will be able to control or exert substantial influence over all matters submitted to our stockholders for approval, including the election of directors and amendments of our organizational documents, and an approval right over any acquisition or liquidation of New Profusa. Upon the completion of the Business Combination, the Profusa shareholders will hold between approximately 46.1% (if no public shares are redeemed) and 46.5% (if the maximum number of public shares are redeemed). Accordingly, upon the completion of the Business Combination, the Profusa shareholders will be able to control or exert substantial influence over all matters submitted to our stockholders for approval, including the election of directors and amendments of our organizational documents, and an approval right over any acquisition or liquidation of New Profusa. The Profusa shareholders may have interests that differ from those of the other stockholders and may vote in a way with which the other stockholders disagree and which may be adverse to their interests. This concentrated control may have the effect of delaying, preventing or deterring a change in control of New Profusa, could deprive New Profusa’s stockholders of an opportunity to receive a premium for their capital stock as part of a sale